You are currently viewing Immunyx Pharma Selected to Join BLUE KNIGHT™

Immunyx Pharma, a developer of immune modulating therapies for neutrophil-based diseases, has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation LLC and the Biomedical Advanced Research and Development Authority (‘BARDA’) within the Administration for Strategic Preparedness and Response (ASPR), a part of the U.S. Department of Health and Human Services, (HHS).

“We are excited to be accepted by JLABS and BARDA as a Blue Knight company,” said Immunyx Pharma CEO Dr. Seth Salpeter. “By applying our targeted neutrophil nanoparticle (TENN) platform technology to modulate neutrophil toxicity in infectious diseases we aim to provide new avenues for combatting public health threats.”

Blue Knight is a collaboration dedicated to anticipating public health security threats, activating the global innovation community, and amplifying scientific and technology advancements to respond to a rapidly evolving global health environment.

Immunyx Pharma is focused on overcoming the major roadblocks in neutrophil therapeutics by using targeted nanoparticle delivery and novel payloads with the aim to modify neutrophil toxicity in disease. Currently there are no FDA approved neutrophil modulating therapies due to the challenges of neutropenia and the large number of systemic neutrophils. Immunyx’s technology aims to solve these problems by targeting drugs to diseased neutrophils and repolarizing neutrophils while not depleting them. Immunyx has demonstrated proof of concept data using in vivo models of respiratory and gastrointestinal disease without toxicity. The company is also advancing targeted neutrophil LNPs, delivering and expressing mRNA in neutrophils together with Merck KGA as part of the CanceRNA consortium.

Through Blue Knight, Immunyx will be expanding its US foot-print with laboratory space at JLABS @ NYC. In addition to the US offices & lab, the company maintains an R&D facility in Jerusalem which was launched in 2021 based on technology licensed from the Hebrew University and seed investment from VLX Ventures. The platform was developed in the laboratories of Professor Zvika Granot and Professor Zvi Fridlender, world-renowned experts in neutrophil biology and repolarization. Immunyx is also supported by a strong international scientific advisory board of clinical experts in human immunological diseases and scientific leaders in the field of nanoparticle delivery.

Currently, Immunyx Pharma is seeking Series A financing for IND-enabling studies and Phase 1 clinical trials.

About Immunyx Pharma

Immunyx Pharma is a drug development company focused on modulating neutrophil function to treat disease. The company was founded based on technology from the Hebrew University with the backing of VLX Ventures. Established in 2021 with offices in Jerusalem and New York City, Immunyx uses the company’s platform technology to specifically manipulate neutrophils using a targeted nanoparticle. Immunyx Pharma will bring new therapies to several diseases where neutrophil treatment could advance a cure, such as CPD, Arthritis, Colitis and certain cancers.

The Immunyx Pharma team has published several high-impact papers on the role of immune cell polarization in cancer response and has several key opinion leaders who have brought 6 nanoparticle drugs to clinical trials. In total, the team has published over 50 papers on cancer immunology and nanoparticle delivery.

In addition to their in-house development programs, Immunyx Pharma is highly interested in collaboration with Pharma partners. Numerous drugs targeting neutrophils and the immune microenvironment have failed due to systemic toxicity or poor drug delivery.

Immunyx Pharma‘s platform allows partners to use their existing drugs or new pipeline molecules with an enhanced level of accuracy and efficacy by packaging them in their targeted nanoparticles.

By combining tools and technologies Immunyx Pharma is able to reshape the landscape of drug treatment bringing the patient better results and less side effects.

For more information please visit Immunyx Pharma

Contacts: Seth Salpeter, seth AT, Tel:  516-340-3189

Source: Csion PR Newswire


About JLM- BioCity

News on the many life science and healthcare companies in the Jerusalem area can be seen at

JLM-BioCity  is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.

We invite you, researcher, professional, investor and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.

If you want your Company featured in our blogs , news releases, please contact: info at